Skip to nav Skip to content

Clinical Trial Search

294 Clinical Trials Found

Clinical Trial 21024

A Phase IIa Study of Dendritic Cell Vaccines against HER2/HER3 and Pembrolizumab in Patients with Asymptomatic Brain Metastasis from Triple Negative Breast Cancer (TNBC) or HER2+ Breast Cancer (HER2+BC)
Disease Site: Brain and Nervous System
PI: Forsyth, Peter

Clinical Trial 20937

A Multicenter, Phase II Trial of Pembrolizumab and Sunitinib In Refractory Advanced Thymic Carcinoma
Disease Site: Other Respiratory and Intrathoracic Organs
PI: Tanvetyanon, Tawee

Clinical Trial 21143

Disease Site: Mycosis Fungoides
PI: Sokol, Lubomir

Clinical Trial 21122

A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of AZD0486, a Bispecific Antibody Targeting CD19 in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Disease Site: Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
PI: Gaballa, Sameh

Clinical Trial 20641

A Randomized Pilot Trial of Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib and Binimetinib in Advanced Melanoma
Disease Site: Melanoma, skin
PI: Eroglu, Zeynep

Clinical Trial 19319

InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)
Disease Site: Penis / penile cancer, Other Male Genital
PI: Spiess, Philippe

Clinical Trial 22574

Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
Disease Site: Any Site, Melanoma, skin
PI: Tarhini, Ahmad

Clinical Trial 22617

Disease Site: Breast
PI: Soyano Muller, Aixa

Clinical Trial 22379

Disease Site: Multiple Myeloma
PI: Castaneda Puglianini, Omar

Clinical Trial 22256

A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Treatment after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM)
Disease Site: Other
PI: Alsina, Melissa

Clinical Trial 22484

PRAGMATICA LUNG: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) plus Pembrolizumab (MK-3475; NSC 776864) versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer
Disease Site: Lung
PI: Saltos, Andreas

Clinical Trial 23102

Disease Site: Brain and Nervous System
PI: Sandoval-Sus, Jose